Evidence map›Paper›PMID 26624556›Full record

ArticleJournal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics2016

Brimonidine Can Prevent In Vitro Hydroquinone Damage on Retinal Pigment Epithelium Cells and Retinal Müller Cells.

Claudio Ramírez, Javier Cáceres-del-Carpio, Justin Chu, Joshua Chu, M Tarek Moustafa, Marilyn Chwa, G Astrid Limb, Baruch D Kuppermann, M Cristina Kenney

Abstract read
In one paragraph

Article in Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Resvega Alleviates Hydroquinone-Induced Oxidative Stress in ARPE-19 Cells.International journal of molecular sciences · 2020
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 3 countries.

Claudio Ramírez1 Gavin Herbert Eye Institute, University of California , Irvine, Irvine, California.
Javier Cáceres-del-Carpio1 Gavin Herbert Eye Institute, University of California , Irvine, Irvine, California.
Justin Chu1 Gavin Herbert Eye Institute, University of California , Irvine, Irvine, California.
Joshua Chu1 Gavin Herbert Eye Institute, University of California , Irvine, Irvine, California.
M Tarek Moustafa1 Gavin Herbert Eye Institute, University of California , Irvine, Irvine, California.
Marilyn Chwa1 Gavin Herbert Eye Institute, University of California , Irvine, Irvine, California.
G Astrid Limb3 Division of Ocular Biology and Therapeutics, UCL Institute of Ophthalmology , London, United Kingdom .
Baruch D Kuppermann1 Gavin Herbert Eye Institute, University of California , Irvine, Irvine, California.
M Cristina Kenney1 Gavin Herbert Eye Institute, University of California , Irvine, Irvine, California.
University of California, Irvine · USUniversity College London · GB

Funding

University of California Health Participation in the National COVID Cohort Collaborative (N3C)UL1TR001414 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI COOPER, DAN M, VILAIN, ERIC J. · 2015 to 2023
$35.1M
Medical Research Council MR/K008722/1NCATS NIH HHS UL1 TR001414
6 · The paper itself

Abstract

purposeBrimonidine is a selective alpha-2 adrenergic agonist used to reduce intraocular pressure and it has been shown to have some neuroprotective effects. Hydroquinone (HQ) is a toxicant present in cigarette smoke, and other sources. In this study, we investigated the cyto-protective effects in vitro of Brimonidine on human retinal pigment epithelium cells (ARPE-19) and human retinal Müller cells (MIO-M1) that had been treated with HQ.

methodsCells were pretreated for 6 h with different doses of Brimonidine tartrate 0.1% (1/2×, 1×, 5×, 10×), followed by a 24-h exposure to 100 μM of HQ, while the Brimonidine was still present. Assays were used to measure cell viability, mitochondrial membrane potential (ΔΨm), reactive oxygen species (ROS) production, and lactate dehydrogenase (LDH) release.

resultsBrimonidine increased the cell viability at all concentrations studied in both cell lines studied. ΔΨm also improved at all Brimonidine doses in ARPE-19 cells and in the 5× and 10× dosages MIO-M1 cells. The ROS levels decreased at 1×, 5×, and 10× doses of Brimonidine in ARPE-19 but only at 10× on MIO-M1 cells. The 10×-Brimonidine ARPE-19 cells had decreased LDH release, but no LDH changes were observed on MIO-M1 cells.

conclusionHQ-induced toxicity is mediated through mitochondrial damaging, oxidative stress-related and necrosis-related pathways; Brimonidine significantly prevented the mitochondrial damaging and oxidative stress-related effects but had little effect on blocking the necrosis component of HQ-toxicity. Brimonidine protective effects differ between the different retinal cell types and high concentrations of Brimonidine (10×) have minimal damaging effects on human retinal cells.

Indexed as

Antihypertensive AgentsApoptosisBrimonidine TartrateCells, CulturedCytoprotectionEpendymoglial CellsHumansHydroquinonesIn Vitro TechniquesL-Lactate DehydrogenaseMembrane Potential, MitochondrialOxidative StressReactive Oxygen SpeciesRetinal Pigment EpitheliumAntihypertensive AgentsBrimonidine TartrateHydroquinonesL-Lactate DehydrogenaseReactive Oxygen Species

Identifiers

PMID26624556
PMCPMC6445176
OpenAlexW2189185302

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.